Low aggregate index of systemic inflammation predicts better survival in hepatocellular carcinoma

Low levels of aggregate index of systemic inflammation (AISI) correlate with better survival in hepatocellular carcinoma (HCC) patients. The study found that lower AISI levels were associated with increased abundance of the gut bacterium Parabacteroides and specific fecal metabolites like cavipetin A. These findings suggest that AISI could be a prognostic biomarker for HCC, with gut microbiota and host metabolism potentially influencing systemic inflammation in the disease.